Core Viewpoint - The article highlights the graduation of ASEAN students from Guangxi University of Science and Technology, focusing on their aspirations and experiences in China, particularly in the fields of medicine and entrepreneurship [1][3]. Group 1: Student Experiences - Mary Wen, a Laotian student, expressed gratitude for her family's support during her graduation, emphasizing her dream of becoming a doctor and the advanced medical education she received in China [3]. - Overcoming language barriers was a significant challenge for Mary Wen, who was the only foreign student in her class, but she successfully integrated into local life with the help of her Chinese classmates [3]. - Mary Wen's clinical practice in Chinese hospitals, including rotations in emergency, internal, and surgical departments, was a valuable experience that she plans to utilize in her future medical career in Laos [3]. Group 2: Aspirations of Indonesian Students - Lin Jianquan and Lin Wanyong, siblings from Indonesia, pursued their studies in China to deepen their understanding of the country, with Lin Jianquan majoring in International Economics and Trade [4]. - Lin Jianquan's mother traveled from Indonesia to attend his graduation, expressing pride and excitement about visiting China [4]. - Lin Jianquan aims to return to Indonesia to start a business, inspired by China's advancements in sectors like new energy vehicles, drones, and 5G technology [4]. - Lin Wanyong, influenced by her brother, also studied in Guangxi and plans to establish a Chinese language training institution in Indonesia after graduation, aiming to promote Chinese culture [4]. Group 3: Educational Context - Guangxi is noted as one of the provinces in China with the highest number of ASEAN students, currently hosting over 6,500 students from ASEAN countries [4].

Financial Data and Key Metrics Changes - Research and development revenue for Q4 2024 was $7.6 million, up from $5.3 million in the prior year, reflecting increased work under the BARDA PBS contract [20] - Full year 2024 R&D revenue reached $29.6 million, a 63.5% increase from $18.1 million in 2023, marking the highest revenue in the company's history [22] - Gross margin for Q4 2024 declined to 44% from 46.1% in the prior year, primarily due to a smaller percentage of direct labor on the BARDA PBS contract [21] - Full year gross margin rose to 44.9% from 43.6% in the prior year, driven by a higher reimbursement rate under the current BARDA PBS contract [22] - General and administrative expenses decreased to $4.6 million in Q4 2024 from $5.4 million in the prior year [21] Business Line Data and Key Metrics Changes - The DeepView system demonstrated exceptional performance in predicting burn healing potential, significantly outperforming clinical judgment in sensitivity, DICE score, and specificity [10][11] - The company plans to submit results to the FDA by the end of Q2 2025, seeking de novo classification in 2026 [12] Market Data and Key Metrics Changes - The response to the DeepView system in the UK and Australia has been exceptional, with strong enthusiasm from medical specialists [14] - Three DeepView systems have been successfully deployed in leading hospitals in Australia, enhancing the company's presence in the region [15] Company Strategy and Development Direction - The company is focused on advancing its DeepView technology for wound and burn assessment, with key milestones in regulatory pathways and clinical validation [8] - Plans include gathering real-world clinical feedback across multiple continents to support FDA submissions and commercialization strategies [13] - The formation of Spectral IP aims to monetize intellectual property assets within healthcare and AI sectors, with a planned spin-off into an independent publicly traded company [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's progress and the potential for growth, emphasizing a focus on finance, focus, and finish [27] - The company anticipates a revenue forecast of approximately $21.5 million for fiscal year 2025, with expectations of a step back in revenue as it prepares for FDA submission [26][45] Other Important Information - The company has received over $7 million in government funding for the development of the Snapshot M diagnostic tool, which is expected to be ready for military deployment in 2027 [16] - Total monthly operating losses were reduced from $4.6 million in the first half of 2024 to approximately $2 million in the second half [25] Q&A Session Summary Question: Plans for commercialization and staffing - The company plans to precondition the market with studies and mobilize a sales force as they anticipate FDA clearance for commercialization [31][32] Question: Revenue guidance for 2025 - The company expects a slight decrease in revenue for 2025 as it positions for FDA submission, with a ramp-up anticipated in 2026 [44][45] Question: FDA submission requirements - The submission will include a comprehensive package with multiple sections, all reviewed by BARDA before submission to the FDA [46][47] Question: DICE score significance - The DICE score is crucial for evaluating segmentation tasks and is important for FDA assessments, balancing precision and recall [51][52] Question: Future deployments in Australia and the UK - The company does not plan to expand the number of units but will focus on deeper utilization and feedback from existing sites [53][54] Question: Pediatric study timeline - Data from the pediatric study is merged with adult data, and the company feels confident in the representative sample for FDA submission [62] Question: Development milestones for Snapshot M - The company is incorporating preliminary feedback from military assessments and plans to submit further applications in 2026 [63][64] Question: Learnings from UK deployments - Positive feedback has been received from UK users, and the company anticipates sharing data at upcoming scientific meetings [67][68]